Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Cancer Diagnosis in a Cohort of Patients with Sjogren's Syndrome and Rheumatoid Arthritis: A Single-center Experience and Review of the Literature

STERGIOS BOUSSIOS, GEORGE PENTHEROUDAKIS, GEORGE SOMARAKIS, THEODORA E. MARKATSELI, ALEXANDROS A. DROSOS and NICHOLAS PAVLIDIS
Anticancer Research November 2014, 34 (11) 6669-6676;
STERGIOS BOUSSIOS
1Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEORGE PENTHEROUDAKIS
1Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEORGE SOMARAKIS
2Department of Internal Medicine-Division of Rheumatology, Ioannina University Hospital, Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
THEODORA E. MARKATSELI
2Department of Internal Medicine-Division of Rheumatology, Ioannina University Hospital, Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALEXANDROS A. DROSOS
2Department of Internal Medicine-Division of Rheumatology, Ioannina University Hospital, Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NICHOLAS PAVLIDIS
1Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: npavlid@uoi.gr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: With the development of modern therapies and better care of patients with autoimmune rheumatic diseases (ARDs) increased survival has been achieved. However, ARDs may share an association with risk of lymphomas and solid tumors. The increased cancer risk in these patients is mainly due to high inflammatory activity and severity of disease, rather than the immunosuppressive therapy. Patients and Methods: We studied the coexistence or later development of cancer with ARDs in a retrospective audit of a reference university hospital and critically reviewed published literature. Fourteen out of 1,730 patients with rheumatoid arthritis (RA) and Sjogren's syndrome (SS) followed-up at the University Hospital of Ioannina over the last 33 years developed secondary malignancies, both solid tumors and lymphomas. Results and Conclusion: The most frequent cancer associated with ARDs is diffuse large B-cell lymphoma (DLBCL). The average risk of lymphoma in RA may be composed of a markedly increased risk in patients with most severe disease. Solid tumors were presented mainly in RA patients and renal cell carcinoma was the most frequently found.

  • Rheumatic disease
  • malignancy
  • paraneoplastic syndromes
  • cancer immunity

The dual relationship between autoimmunity and cancer has long been recognized. It has been shown that there is an increased risk of malignancies, mainly non-Hodgkin lymphoma (NHL), in patients with rheumatoid arthritis (RA), Sjogren's syndrome (SS), and systemic lupus erythematosus (SLE) (1-8). In initial studies (7, 8), the more indolent mucosa-associated lymphoid tissue (MALT) lymphoma was the most common lymphoma seen in primary SS. Mechanisms that possibly contribute to the increased incidence of lymphoma in autoimmune rheumatic diseases (ARDs) include immune dysregulation, resistance to apoptosis and prolonged survival of B cells, chronic antigenic stimulation and challenged T-cell function. At the molecular level, the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) appears to be a key connecting element between inflammation and cancer (16). NF-κB is a central intracellular transducer of inflammatory signals integrating signals from a variety of environmental changes, including infection, tissue damage and autoimmunity (16, 17). The role of immunosuppressive medications in the development of cancer and/or lymphoma in SLE is still controversial. Non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticosteroids do not appear to be associated with increased risk of malignancy in patients with RA or other ARDs (1, 18). The overall malignancy risk attributable to methotrexate treatment in patients with ARDs does not appear to be increased, although there are numerous reports suggesting that the risk of lymphoproliferative diseases may be increased. When patients are on long-term immunosuppressive medications, the odds of cancer development are increased (19, 20). It has also not been shown an increased risk of malignancies associated with anti-TNF (tumor necrosis factor) treatment for RA (21). In some cases, common environmental risk factors for chronic inflammatory diseases and malignancy contribute to increased comorbidity (22). In the present article, we are presenting our experience on this association by describing 14 cases from our cohort with ARDs who developed hematological and non-hematological malignancies.

Materials and Methods

The records of patients with ARDs diagnosed and treated at the Rheumatology Department of Ioannina University Hospital, Greece, were investigated from 1981 to 2013 for the development of malignant diseases. Patients diagnosed with SS and RA were included in this study. Types of cancer, anticancer treatment and survival were analyzed. Also, the elapsed time from the diagnosis of ARDs to cancer development as well as the administration of various anti-rheumatic treatments was recorded.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Cancer diagnosis in patients with ARDs: Demographics.

Results

Cancer detection. Fourteen patients with cancer were retrieved in total among 1,730 patients with RA and SS from the database of the University hospital of Ioannina, Greece, between 1981 and 2013 (Table I). Ten cases with cancer were identified out of 1,280 patients with RA, (incidence of 0.8%), and 5 out of the 450 patients with SS, (incidence of 1.1%). One patient had secondary SS with RA.

Autoimmune parameters. RA accounted for the majority of the patients (10/15) and almost all of them presented with moderate or severe disease. We identified these 10 cases diagnosed with a secondary malignancy out of 1,280 patients with RA that were registered in the Rheumatology division from 1981 (0.8%). The median age at RA diagnosis was 43.1 (range=22-55). Six were females. The median time from the diagnosis of RA to the development of malignancy was 18.4 years (range=1-30 years). The median follow up was 53.4 months (range=3-132 months). Concerning anti-rheumatic treatment, eight patients received methotrexate and seven anti-TNF agents i.e. infliximab. SS patients with malignancy had a median age at SS diagnosis of 38.7 years (range=27-47 years) and three of them were females. The median time from SS diagnosis to cancer detection was 25.3 years (range=20-30 years). One patient had localized and the rest extensive disease. Only two patients were treated with methotrexate. The median follow-up was estimated to be 34 months (2-63 months). All data are presented in Tables I and II.

Cancer parameters. The mean age of the autoimmune patients at the time of the diagnosis of cancer was 62.6 years (range=52-72 years) with a strong female predisposition (8 out of 15 patients). Seven patients diagnosed with ARDs developed lymphomas. Five of them presented with diffuse large B-cell lymphoma (DLBCL) of stage IV in three cases and stage II in the rest two patients. The remaining two patients were diagnosed with extranodal marginal zone lymphoma of stage IV and nodular sclerosis Hodgkin's lymphoma of stage IIIBs, respectively. All patients were treated with chemotherapy, 5 of whom enjoyed long term survival.

Eight ARDs patients developed solid tumors. Seven of them had RA and were diagnosed with renal cell carcinomas of stage I and of grade III in three cases and the rest with hepatocellular, colon, breast carcinomas, as well as pulmonary carcinoid tumor. Only two patients with solid tumors (hepatocellular carcinoma and colon cancer) presented with metastatic disease. The remaining cases had early-stage disease. As far as systemic treatment is concerned, four out of eight patients received chemotherapy, endocrine or targeting therapy and some of them experienced long-term survival.

Discussion

The direct link between autoimmunity and lymphoma development has been supported by large epidemiological studies showing a consistent risk increase of lymphoma associated with certain autoimmunity and inflammatory conditions in independent cohorts from different countries. It is apparent that the magnitude of the risk estimates varies considerably between studies. Earlier and smaller studies on selected patients typically reported higher risk estimates compared to more recent, larger and population-based studies (23-25). The highest relative risk (RR) for lymphoma is associated with primary Sjogren's syndrome (pSS), followed by SLE and RA, indicating a disease-specific risk profile (26). Data from all available population-based register studies with estimates of lymphoma, breast, lung and colorectal cancer in patients with ARDs are depicted in Table III.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Treatment and survival characteristics.

The most frightening complication of pSS is lymphoproliferative disease. This is a chronic excessive salivary and lacrimal gland B cell stimulation and impaired B cell apoptosis that leads to tumorigenesis and clonal expansion of B cells. In large cohorts, the estimated odds ratio of lymphoma in SS was between 2.0 and 18.8 (27, 28). A recent population-based case-control study found that marginal zone lymphoma was most strongly associated with SS, followed by DLBCL and that these associations remained significant when the 5-year period prior to diagnosis was excluded (29). In contrast, several clinical analyses indicated that MALT and DLBCL lymphomas occurred at a similar frequency (30). It is also observed that the RR of developing lymphoma was about 16-fold higher in SS patients than in the general population and that this risk is increased over time and remained high, even 15 years after pSS diagnosis (30). The overall 10-year survival rates were estimated to be 91% for patients with SS and 69% for patients who developed lymphoma (31). Moreover, some studies have reported that pSS patients who developed lymphoma were at higher risk of developing a second malignancy, probably due to suppressed immunity (32). The salivary glands are the most common site of lymphoma development but extra-nodal sites are also involved, including the stomach, nasopharynx, skin, liver, kidneys, lungs, lymph nodes and bone marrow (33). SS may occur alone (primary SS) or in association with another ARD, defined as secondary SS. Secondary SS can be associated with SLE. The Inter Lymph consortium of non-Hodgkin's lymphoma (NHL) case-control studies found that patients with secondary SS were at higher risk of NHL development than patients with pSS, with similar RR for NHL subtypes (8). Nevertheless, in our series of patients with SS, 1 among 5 who diagnosed with lymphomas was determined with MALT type. However, 3 of them developed DLBCL, which is in accordance with the literature. The latency period between the onset of the SS and the time of the lymphoma diagnosis was 65 months (31). This period of time is much more prolonged in our experience with a median time of 25.3 years from the diagnosis of SS to the development of the lymphoma (range=20-30 years) (Table II). Gender differences in risk have not been robustly evaluated due to the heavy predominance of female patients in SS (8, 34-38). In our cases the females patients were 3 out of 5. Established risk factors for predicting lymphoma development in SS patients include lymphadenopathy, parotid enlargement, splenomegaly, peripheral neuropathy, purpura or skin vasculitis (5, 39). Recent laboratory findings have shown that cryoglobulinemia, low complement levels of C4 and C3 and lymphocytopenia are suggested risk factors (8, 40). Some viruses (Epstein–Barr virus (EBV), human herpes virus (HHV-8) (41, 42) and bacteria (H. pylori, Chlamydia psittaci) (43, 44) have been proposed as possible triggers for NHL development, especially in the MALT-subtype. Nevertheless, we did not find any relationship between infectious agents and lymphoma development in our series.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Literature review of cancer risk in RA and SS (2006-2014).

The risk of cancer has been extensively studied in patients with RA. An increased risk of developing lymphoproliferative cancers was found among both women and men with RA in a large study (45). Similarly, in a meta-analysis of 21 publications from 1990 to 2007 on the risk of malignancy in patients with RA, the risk of lymphoma was increased approximately two-fold standardized incidence ratio (SIR) (2.08, 95% confidence interval (CI)=1.8, 2.39) (46).

The possible mechanisms for increased risk of hematological cancers in RA include the persistent immune stimulation, the decreased number and function of suppressor T-cells and the decreased activity of natural killer cells in the synovial fluid, tissue, blood and lymph (47). According to a study, during the first 10 years following diagnosis of RA, the overall RR of lymphoma development was 1.75 (95% CI=1.04-2.96). An increased risk of lung cancer was also observed (48). Patients with RA are at high risk for DLBCL, which has been reported to represent up to two-thirds of the NHLs in patients with RA (49-51). In RA, a clear correlation has been demonstrated between lymphoma risk and features linked to disease severity, such as the presence of Felty's syndrome (52), secondary SS (4), high erythrocyte-sedimentation rate values (3) and erosive joint disease (1, 53). This association is stronger in cases reporting severe RA disease than in those with mild disease, as well as among patients who have positive rheumatoid factor (1, 51). In our series, all 3 patients with RA who developed NHL were identified with DLBCL. Two of them had severe disease, which is in accordance to the literature. We report the presence of renal cancer (3 out of 10) and hepatocellular carcinoma (1 out of 10), which are uncommon secondary malignancies in RA patients.

According to Askling et al. there was a moderate increase in the risk of developing lung cancer in patients with RA compared to the general population (54). Cigarette smoking would explain an indirect association between RA and lung cancer as smoking is an independent risk factor for both conditions. The mortality from pulmonary disease in RA is approximately twice that of the general population (55). Our report adds one more case of pulmonary carcinoid tumor as a secondary malignancy in patients with RA.

The explanation for the reduced risk of colorectal cancer is most likely due to the increased use of NSAIDs and cyclooxygenase-2 (COX-2)-selective inhibitors by patients with RA (46). A meta-analysis of randomized controlled trials and observational studies concluded that COX-2 inhibitors and NSAIDs reduce the incidence of colonic adenomas and that NSAIDs also reduce the incidence of colorectal cancer (56).

Numerous immunosuppressive drugs have been used to treat ARDs. Some of these agents may directly or indirectly be associated with the subsequent development of malignancies. Among traditional immunosuppressive drugs only cyclophosphamide was found to be definitely carcinogenic with an increased risk of hematologic malignancies (57).

Disease-modifying anti-rheumatic drugs, including methotrexate, azathioprine and other immunosuppressive substances have been repeatedly suggested as a risk factor for RA-associated lymphomas (58-60). However, studies with detailed information on markers of inflammatory activity, as well as treatment (1, 3, 53, 61), did not substantiate the proposed treatment-related increase in lymphoma risk, with the possible exception of azathioprine (1, 62-64). Nevertheless, sustained clinical activity of RA may be the primary risk factor for secondary malignancies and methotrexate may have a net beneficial effect in this respect (51, 61, 65).

In addition, there has been a debate whether biological agents, predominantly TNF inhibitors, would or would not increase the risk for the development of malignancies, primarily lymphomas. In a meta-analysis published in 2012, Solomon et al. did not demonstrate increased incidence of cancer development related to the use of biological agents (66). Similarly, Askling and colleagues (54) presented SIRs for various solid tumors and reported no difference in patients with RA who received anti-TNF medication compared with the general population for lung and colorectal cancer. A meta-analysis of randomized clinical trials from 2009 found that the use of etanercept for 12 weeks or more in patients with RA was associated with a non-significant increase in the incidence of cancer (67). Similar overall rates of cancer as in the general RA population was found in patients treated with abatacept that inhibits T-cell activation (68). A recent study found no increase in the overall cancer rate in patients treated with rituximab, a chimeric monoclonal antibody against the protein CD20, compared to those treated with disease-modifying anti-rheumatic drugs (69, 70). Nevertheless, in our series 2 out of 3 patients with RA who developed lymphoma were treated with TNF antagonists. We also report 6 from a total of 7 patients with RA, treated with anti-TNF drugs who developed solid tumors.

In conclusion, in this article we presented our experience in a cohort of autoimmune patients who developed hematological malignancies and solid tumors during their disease evolution. In a period of 33 years, 14 patients with RA and SS developed cancer. Eight developed lymphomas and the rest various epithelial carcinomas. We also extensively discussed the possible carcinogenic effect of anti-autoimmune treatment.

  • Received July 1, 2014.
  • Revision received August 5, 2014.
  • Accepted August 7, 2014.
  • Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Baecklund E,
    2. Iliadou A,
    3. Askling J,
    4. Ekbom A,
    5. Backlin C,
    6. Granath F,
    7. Catrina AI,
    8. Rosenquist R,
    9. Feltelius N,
    10. Sundström C,
    11. Klareskog L
    :Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54: 692-701, 2006.
    OpenUrlCrossRefPubMed
    1. Baecklund E,
    2. Askling J,
    3. Rosenquist R,
    4. Ekbom A,
    5. Klareskog L
    :Rheumatoid arthritis and malignant lymphomas.Curr Opin Rheumatol 16: 254-261, 2004.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Wolfe F
    : Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arthritis: a 25-year study of 1,767 RA patients [abstract]. Arthritis Rheum 41(Suppl 9): 188, 1998.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Kauppi M,
    2. Pukkala E,
    3. Isomäki H
    : Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 8: 201-204, 1997.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Ioannidis JP,
    2. Vassiliou VA,
    3. Moutsopoulos HM
    : Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 46: 741-747, 2002.
    OpenUrlCrossRefPubMed
    1. Zhang W,
    2. Feng S,
    3. Yan S,
    4. Zhao Y,
    5. Li M,
    6. Sun J,
    7. Zhang FC,
    8. Cui Q,
    9. Dong Y
    : Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. Rheumatology (Oxford) 49: 571-577, 2010.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Voulgarelis M,
    2. Dafni UG,
    3. Isenberg DA,
    4. Moutsopoulos HM
    : Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 42: 1765-1772, 1999.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Theander E,
    2. Henriksson G,
    3. Ljungberg O,
    4. Mandl T,
    5. Manthorpe R,
    6. Jacobsson LT
    : Lymphoma and other malignancies in primary Sjogren's syndrome. A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65: 796-803, 2006.
    OpenUrlAbstract/FREE Full Text
    1. Turnbull AR,
    2. Turner DT,
    3. Fraser JD,
    4. Lloyd RS,
    5. Lang CJ,
    6. Wright R
    : Autoantibodies in early breast cancer: a stage-related phenomenon? Br J Cancer 38: 461-463, 1978.
    OpenUrlPubMed
    1. Wasserman J,
    2. Glas U,
    3. Blomgren H
    : Autoantibodies in patients with carcinoma of the breast. Correlation with prognosis. Clin Exp Immunol 19: 417-422, 1975.
    OpenUrlPubMed
    1. Zeromski JO,
    2. Górny MK,
    3. Jarczewska K
    :Malignancy associated with antinuclear antibodies. Lancet 2(7785): 1035-1036, 1972.
    OpenUrlPubMed
    1. Thomas PJ,
    2. Kaur JS,
    3. Aitcheson CT,
    4. Robinson WA,
    5. Tan EM
    : Antinuclear, antinucleolar, and anticytoplasmic antibodies in patients with malignant melanoma.Cancer Res 43: 1372-1380, 1983.
    OpenUrlAbstract/FREE Full Text
    1. Betterle C,
    2. Peserico A,
    3. Bersani G,
    4. Ninfo V,
    5. Del Prete GF,
    6. Stefani R,
    7. Nitti D
    : Circulating antibodies in malignant melanoma patients. Dermatologica 159: 24-29, 1979.
    OpenUrlPubMed
    1. Kiyosawa K,
    2. Daemer RJ,
    3. He LF,
    4. Bonino F,
    5. Prozesky OW,
    6. Purcell RH
    : The spectrum of complement-fixing antinuclear antibodies in patients with hepatocellular carcinoma.Hepatology 5: 548-555, 1985.
    OpenUrlPubMed
    1. Seiner M,
    2. Klein E,
    3. Klein G
    : Antinuclear reactivity of sera in patients with leukemia and other neoplastic diseases. Clin Immunol Immunopathol 4: 374-381, 1975.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Ben-Neriah Y,
    2. Karin M
    : Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 12: 715-723, 2011.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Barnes PJ,
    2. Karin M
    : Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 12: 1066-1071, 1997.
    OpenUrl
  9. ↵
    1. Bernatsky S,
    2. Lee JL,
    3. Rahme E
    : Non-Hodgkin's lymphoma--meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories. Rheumatology (Oxford) 46: 690-694, 2007.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Engels EA,
    2. Pfeiffer RM,
    3. Fraumeni JF Jr.,
    4. Kasiske BL,
    5. Israni AK,
    6. Snyder JJ,
    7. Wolfe RA,
    8. Goodrich NP,
    9. Bayakly AR,
    10. Clarke CA,
    11. Copeland G,
    12. Finch JL,
    13. Fleissner ML,
    14. Goodman MT,
    15. Kahn A,
    16. Koch L,
    17. Lynch CF,
    18. Madeleine MM,
    19. Pawlish K,
    20. Rao C,
    21. Williams MA,
    22. Castenson D,
    23. Curry M,
    24. Parsons R,
    25. Fant G,
    26. Lin M
    : Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306: 1891-1901, 2011.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Naldi L
    : Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol 28: 88-92, 2010.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Askling J,
    2. van Vollenhoven RF,
    3. Granath F,
    4. Raaschou P,
    5. Fored CM,
    6. Baecklund E,
    7. Dackhammar C,
    8. Feltelius N,
    9. Cöster L,
    10. Geborek P,
    11. Jacobsson LT,
    12. Lindblad S,
    13. Rantapää-Dahlqvist S,
    14. Saxne T,
    15. Klareskog L
    : Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 60: 3180-3189, 2009.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Källberg H
    : Rheumatoid arthritis and lung cancer: you probably heard it before. J Rheumatol 35: 1695-1696, 2008.
    OpenUrlFREE Full Text
  14. ↵
    1. Smedby KE,
    2. Baecklund E,
    3. Askling J
    : Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics.Cancer Epidemiol Biomarkers Prev 15: 2069-2077, 2006.
    OpenUrlAbstract/FREE Full Text
    1. Smedby KE,
    2. Askling J,
    3. Mariette X,
    4. Baecklund E
    : Autoimmune and inflammatory disorders and risk of malignant lymphomas--an update.J Intern Med 264: 514-527, 2008.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Dias C,
    2. Isenberg DA
    : Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol 7: 360-368, 2011.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Smedby KE,
    2. Vajdic CM,
    3. Falster M,
    4. Engels EA,
    5. Martínez-Maza O,
    6. Turner J,
    7. Hjalgrim H,
    8. Vineis P,
    9. Seniori Costantini A,
    10. Bracci PM,
    11. Holly EA,
    12. Willett E,
    13. Spinelli JJ,
    14. La Vecchia C,
    15. Zheng T,
    16. Becker N,
    17. De Sanjosé S,
    18. Chiu BC,
    19. Dal Maso L,
    20. Cocco P,
    21. Maynadié M,
    22. Foretova L,
    23. Staines A,
    24. Brennan P,
    25. Davis S,
    26. Severson R,
    27. Cerhan JR,
    28. Breen EC,
    29. Birmann B,
    30. Grulich AE,
    31. Cozen W
    : Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111: 4029-4038, 2008.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Zintzaras E,
    2. Voulgarelis M,
    3. Moutsopoulos HM
    :The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165: 2337-2344, 2005.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Bernatsky S,
    2. Ramsey-Goldman R,
    3. Clarke A
    : Malignancy and autoimmunity. Curr Opin Rheumatol 18: 129-134, 2006.
    OpenUrlPubMed
  19. ↵
    1. Anderson LA,
    2. Gadalla S,
    3. Morton LM,
    4. Landgren O,
    5. Pfeiffer R,
    6. Warren JL,
    7. Berndt SI,
    8. Ricker W,
    9. Parsons R,
    10. Engels EA
    : Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 125: 398-405, 2009.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Solans-Laqué R,
    2. López-Hernandez A,
    3. Bosch-Gil JA,
    4. Palacios A,
    5. Campillo M,
    6. Vilardell-Tarres M
    : Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum 41: 415-423, 2011.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Suvajdzic N,
    2. Djurdjevic P,
    3. Todorovic M,
    4. Perunicic M,
    5. Stojanović R,
    6. Novkovic A,
    7. Mihaljevic B
    : Clinical characteristics of patients with lymphoproliferative neoplasms in the setting of systemic autoimmune diseases. Med Oncol 29: 2207-2211, 2012.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Lazarus MN,
    2. Robinson D,
    3. Mak V,
    4. Møller H,
    5. Isenberg DA
    : Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology (Oxford) 45: 1012-1015, 2006.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Voulgarelis M,
    2. Moutsopoulos HM
    : Malignant lymphoma in primary Sjogren's syndrome. Isr Med Assoc J 3: 761-766, 2001.
    OpenUrlPubMed
  24. ↵
    1. Smedby KE,
    2. Hjalgrim H,
    3. Askling J,
    4. Chang ET,
    5. Gregersen H,
    6. Porwit-MacDonald A,
    7. Sundström C,
    8. Akerman M,
    9. Melbye M,
    10. Glimelius B,
    11. Adami HO
    : Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98: 51-60, 2006.
    OpenUrlAbstract/FREE Full Text
    1. Valesini G,
    2. Priori R,
    3. Bavoillot D,
    4. Osborn J,
    5. Danieli MG,
    6. Del Papa N,
    7. Gerli R,
    8. Pietrogrande M,
    9. Sabbadini MG,
    10. Silvestris F,
    11. Valsecchi L
    : Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjogren's syndrome. J Rheumatol 24: 2376-2380, 1997.
    OpenUrlPubMed
    1. Davidson BK,
    2. Kelly CA,
    3. Griffiths ID
    : Primary Sjogren's syndrome in the north east of England: a long-term follow-up study. Rheumatology (Oxford) 38: 245-253, 1999.
    OpenUrlAbstract/FREE Full Text
    1. Pertovaara M,
    2. Pukkala E,
    3. Laippala P,
    4. Miettinen A,
    5. Pasternack A
    : A longitudinal cohort study of Finnish patients with primary Sjogren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 60: 467-472, 2001.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Engels EA,
    2. Cerhan JR,
    3. Linet MS,
    4. Cozen W,
    5. Colt JS,
    6. Davis S,
    7. Gridley G,
    8. Severson RK,
    9. Hartge P
    : Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. Am J Epidemiol 162: 1153-1161, 2005.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Baimpa E,
    2. Dahabreh IJ,
    3. Voulgarelis M,
    4. Moutsopoulos HM
    : Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 88: 284-293, 2009.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Ismail F,
    2. Mahmoud A,
    3. Abdelhaleem H,
    4. Mamdoh A,
    5. Geneidy M,
    6. Kamal E
    : Primary Sjögren's syndrome and B-non-Hodgkin lymphoma: role of CD4+ T lymphocytopenia.Rheumatol Int 33: 1021-1025, 2013.
    OpenUrlPubMed
  28. ↵
    1. Royer B,
    2. Cazals-Hatem D,
    3. Sibilia J,
    4. Agbalika F,
    5. Cayuela JM,
    6. Soussi T,
    7. Maloisel F,
    8. Clauvel JP,
    9. Brouet JC,
    10. Mariette X
    : Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 90: 766-775, 1997.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Klussmann JP,
    2. Wagner M,
    3. Guntinas-Lichius O,
    4. Müller A
    : Detection of HHV-8 sequences and antigens in a MALT lymphoma associated with Sjögren's syndrome. J Oral Pathol Med 32: 243-245, 2003.
    OpenUrlPubMed
  30. ↵
    1. Nishimura M,
    2. Miyajima S,
    3. Okada N
    : Salivary gland MALT lymphoma associated with Helicobacter pylori infection in a patient with Sjögren's Syndrome. J Dermatol 27: 450-452, 2000.
    OpenUrlPubMed
  31. ↵
    1. Ferreri AJ,
    2. Guidoboni M,
    3. Ponzoni M,
    4. De Conciliis C,
    5. Dell'Oro S,
    6. Fleischhauer K,
    7. Caggiari L,
    8. Lettini AA,
    9. Dal Cin E,
    10. Ieri R,
    11. Freschi M,
    12. Villa E,
    13. Boiocchi M,
    14. Dolcetti R
    : Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 96: 586-594, 2004.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Parikh-Patel A,
    2. White RH,
    3. Allen M,
    4. Cress R
    : Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control 20: 1001-1010, 2009.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Smitten AL,
    2. Simon TA,
    3. Hochberg MC,
    4. Suissa S
    : A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10: R45, 2008.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Georgescu L,
    2. Quinn GC,
    3. Schwartzman S,
    4. Paget SA
    : Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 26: 794-804, 1997.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Hellgren K,
    2. Smedby KE,
    3. Feltelius N,
    4. Baecklund E,
    5. Askling J
    : Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. Arthritis Rheum 62: 1252-1258, 2010.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Baecklund E,
    2. Sundström C,
    3. Ekbom A,
    4. Catrina AI,
    5. Biberfeld P,
    6. Feltelius N,
    7. Klareskog L
    : Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B-cell lymphoma. Arthritis Rheum 48: 1543-1550, 2003.
    OpenUrlCrossRefPubMed
    1. Landgren O,
    2. Engels EA,
    3. Pfeiffer RM,
    4. Gridley G,
    5. Mellemkjaer L,
    6. Olsen JH,
    7. Kerstann KF,
    8. Wheeler W,
    9. Hemminki K,
    10. Linet MS,
    11. Goldin LR
    : Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 98: 1321-1330, 2006.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Franklin J,
    2. Lunt M,
    3. Bunn D,
    4. Symmons D,
    5. Silman A
    : Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community-based prospective study. Arthritis Rheum 56: 790-798, 2007.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Gridley G,
    2. Klippel JH,
    3. Hoover RN,
    4. Fraumeni JF Jr.
    : Incidence of cancer among men with the Felty syndrome.Ann Intern Med 120: 35-39, 1994.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Baecklund E,
    2. Ekbom A,
    3. Sparén P,
    4. Feltelius N,
    5. Klareskog L
    : Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317: 180-181, 1998.
    OpenUrlFREE Full Text
  40. ↵
    1. Askling J,
    2. Fored CM,
    3. Brandt L,
    4. Baecklund E,
    5. Bertilsson L,
    6. Feltelius N,
    7. Cöster L,
    8. Geborek P,
    9. Jacobsson LT,
    10. Lindblad S,
    11. Lysholm J,
    12. Rantapää-Dahlqvist S,
    13. Saxne T,
    14. Klareskog L
    : Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64: 1421-1426, 2005.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Pincus T,
    2. Callahan LF
    : Early mortality in RA predicted by poor clinical status. Bull Rheum Dis 41: 1-4, 1992.
    OpenUrlPubMed
  42. ↵
    1. Rostom A,
    2. Dubé C,
    3. Lewin G,
    4. Tsertsvadze A,
    5. Barrowman N,
    6. Code C,
    7. Sampson M,
    8. Moher D
    : Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146: 376-389, 2007.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Brodsky RA
    : High dose cyclophosphamide treatment for autoimmune disorders. Scientific World Journal 2: 1808-1815, 2002.
    OpenUrlPubMed
  44. ↵
    1. Matteson EL,
    2. Hickey AR,
    3. Maguire L,
    4. Tilson HH,
    5. Urowitz MB
    : Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol 18: 809-814, 1991.
    OpenUrlPubMed
    1. Jones M,
    2. Symmons D,
    3. Finn J,
    4. Wolfe F
    : Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 35: 738-745, 1996.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Asten P,
    2. Barrett J,
    3. Symmons D
    : Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 26: 1705-1714, 1999.
    OpenUrlPubMed
  46. ↵
    1. Wolfe F,
    2. Michaud K
    : Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50: 1740-1751, 2004.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Salliot C,
    2. van der Heijde D
    : Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68: 1100-1104, 2009.
    OpenUrlAbstract/FREE Full Text
    1. Hoshida Y,
    2. Xu JX,
    3. Fujita S,
    4. Nakamichi I,
    5. Ikeda J,
    6. Tomita Y,
    7. Nakatsuka S,
    8. Tamaru J,
    9. Iizuka A,
    10. Takeuchi T,
    11. Aozasa K
    : Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.J Rheumatol 34: 322-331, 2007.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Kandiel A,
    2. Fraser AG,
    3. Korelitz BI,
    4. Brensinger C,
    5. Lewis JD
    : Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54: 1121-1125, 2005.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Bernatsky S,
    2. Clarke AE,
    3. Suissa S
    : Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 168: 378–381, 2008.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Solomon DH,
    2. Mercer E,
    3. Kavanaugh A
    : Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum 64: 21-32, 2012.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Bongartz T,
    2. Warren FC,
    3. Mines D,
    4. Matteson EL,
    5. Abrams KR,
    6. Sutton AJ
    : Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 68: 1177-1183, 2009.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Simon TA,
    2. Smitten AL,
    3. Franklin J,
    4. Askling J,
    5. Lacaille D,
    6. Wolfe F,
    7. Hochberg MC,
    8. Qi K,
    9. Suissa S
    : Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 68: 1819-1826, 2009.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Bagust A,
    2. Boland A,
    3. Hockenhull J,
    4. Fleeman N,
    5. Greenhalgh J,
    6. Dundar Y,
    7. Proudlove C,
    8. Kennedy T,
    9. Moots R,
    10. Williamson P,
    11. Dickson R
    : Rituximab for the treatment of rheumatoid arthritis.Health Technol Assess 13(Suppl 2): 23-29, 2009.
    OpenUrl
  54. ↵
    1. Slimani S,
    2. Lukas C,
    3. Combe B,
    4. Morel J
    : Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine 78: 484-487, 2011.
    OpenUrlCrossRefPubMed
    1. Askling J,
    2. Baecklund E,
    3. Granath F,
    4. Geborek P,
    5. Fored M,
    6. Backlin C,
    7. Bertilsson L,
    8. Cöster L,
    9. Jacobsson LT,
    10. Lindblad S,
    11. Lysholm J,
    12. Rantapää-Dahlqvist S,
    13. Saxne T,
    14. van Vollenhoven R,
    15. Klareskog L,
    16. Feltelius N
    : Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 68: 648-653, 2009.
    OpenUrlAbstract/FREE Full Text
    1. Mercer LK,
    2. Davies R,
    3. Galloway JB,
    4. Low A,
    5. Lunt M,
    6. Dixon WG,
    7. Watson KD,
    8. Symmons DP,
    9. Hyrich KL
    : Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 52: 91-98, 2013.
    OpenUrlAbstract/FREE Full Text
    1. Dreyer L,
    2. Mellemkjær L,
    3. Andersen AR,
    4. Bennett P,
    5. Poulsen UE,
    6. Juulsgaard Ellingsen T,
    7. Hansen TH,
    8. Jensen DV,
    9. Linde L,
    10. Lindegaard HM,
    11. Loft AG,
    12. Nordin H,
    13. Omerovic E,
    14. Rasmussen C,
    15. Schlemmer A,
    16. Tarp U,
    17. Hetland ML
    : Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry. Ann Rheum Dis 72: 79-82, 2013.
    OpenUrlAbstract/FREE Full Text
    1. Weng MY,
    2. Huang YT,
    3. Liu MF,
    4. Lu TH
    : Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan. Ann Rheum Dis 71: 524-527, 2012.
    OpenUrlAbstract/FREE Full Text
    1. Johnsen SJ,
    2. Brun JG,
    3. Gøransson LG,
    4. Småstuen MC,
    5. Johannesen TB,
    6. Haldorsen K,
    7. Harboe E,
    8. Jonsson R,
    9. Meyer PA,
    10. Omdal R
    : Risk of non-Hodgkin's lymphoma in primary Sjögren's syndrome: a population-based study. Arthritis Care Res (Hoboken) 65: 816-821, 2013.
    OpenUrlPubMed
    1. Liang Y,
    2. Yang Z,
    3. Qin B,
    4. Zhong R
    : Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 73: 1151-1156, 2014.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 34 (11)
Anticancer Research
Vol. 34, Issue 11
November 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cancer Diagnosis in a Cohort of Patients with Sjogren's Syndrome and Rheumatoid Arthritis: A Single-center Experience and Review of the Literature
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
12 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Cancer Diagnosis in a Cohort of Patients with Sjogren's Syndrome and Rheumatoid Arthritis: A Single-center Experience and Review of the Literature
STERGIOS BOUSSIOS, GEORGE PENTHEROUDAKIS, GEORGE SOMARAKIS, THEODORA E. MARKATSELI, ALEXANDROS A. DROSOS, NICHOLAS PAVLIDIS
Anticancer Research Nov 2014, 34 (11) 6669-6676;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Cancer Diagnosis in a Cohort of Patients with Sjogren's Syndrome and Rheumatoid Arthritis: A Single-center Experience and Review of the Literature
STERGIOS BOUSSIOS, GEORGE PENTHEROUDAKIS, GEORGE SOMARAKIS, THEODORA E. MARKATSELI, ALEXANDROS A. DROSOS, NICHOLAS PAVLIDIS
Anticancer Research Nov 2014, 34 (11) 6669-6676;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Predictive and Prognostic Value of SUOX Expression in Pancreatic Ductal Adenocarcinoma
  • Liberal Application of Portal Vein Embolization for Right Hepatectomy Against Hepatocellular Carcinoma: Strategy to Achieve Zero Mortality for a Damaged Liver
  • Pancreaticoenterostomy With Seromuscular-parenchymal Anastomosis for Prevention of Postoperative Pancreatic Fistula in Distal Pancreatectomy
Show more Clinical Studies

Similar Articles

Keywords

  • Rheumatic disease
  • malignancy
  • paraneoplastic syndromes
  • Cancer immunity
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire